The Prescription Medicines Code of Practice Authority (PMCPA) issued a formal rebuke against Sanofi for making misleading statements about its RSV monoclonal antibody Beyfortus, alleging it is more effective than Pfizer’s vaccine Abrysvo.
The PMCPA found that Sanofi’s marketing materials claimed Beyfortus provides superior protection against RSV in infants, but the company failed to provide supporting clinical data. The authority cited seven breaches, including the presentation of unsubstantiated efficacy claims and the disparagement of Pfizer’s product.
Under the ABPI Code of Practice, such breaches can lead to public reprimands, mandatory corrections to promotional content, and potential financial penalties. Sanofi has previously faced similar findings, underscoring the importance of accurate and balanced medical information.
Sanofi has not yet issued a formal response to the PMCPA’s findings, but the company has indicated it is reviewing the allegations and will cooperate with the regulator.
The incident highlights the intense competition in the RSV prevention market, where Beyfortus offers passive immunity through a single‑dose monoclonal antibody, while Abrysvo delivers active immunity via vaccination of pregnant individuals or older adults. A regulatory reprimand could erode confidence among healthcare providers and patients, potentially impacting sales and market share as the 2025‑2026 RSV season approaches.
While no immediate market reaction data are available, regulatory actions of this nature typically prompt investors to reassess Sanofi’s marketing strategy and compliance posture, which could influence future earnings forecasts and valuation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.